))
Episode 8: Drug Pricing, Valuing Innovation and No Patient Left Behind with Peter Kolchinsky
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on February 27, 2024 04:28 (
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 337444526 series 3381207
Nội dung được cung cấp bởi Gunnar Esiason. Tất cả nội dung podcast bao gồm các tập, đồ họa và mô tả podcast đều được Gunnar Esiason hoặc đối tác nền tảng podcast của họ tải lên và cung cấp trực tiếp. Nếu bạn cho rằng ai đó đang sử dụng tác phẩm có bản quyền của bạn mà không có sự cho phép của bạn, bạn có thể làm theo quy trình được nêu ở đây https://vi.player.fm/legal.
Biotechnology investor, Peter Kolchinsky, joins the State of Health to talk with Gunnar about drug pricing. The conversation covers the long term view that when drugs go generic without undue delay, the value they provide to society is far greater than the short-run value that cost effectiveness analyses often show, which Peter details in his book, The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines. Peter also talks about his new non-profit, No Patient Left Behind, of which Gunnar is a part, and why out of pocket costs should be seen as the true barriers between innovative medicines and patients. Peter uses the COVID-19 pandemic as a case study for improving access issues insofar that out of pocket costs were largely eliminated for vaccines. No Patient Left behind is on twitter @NPLB_org and on the web at www.nopatientleftbehind.org
To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy
Learn more about your ad choices. Visit https://podcastchoices.com/adchoices
23 tập
Chia sẻ
